01
May

The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.

…read more

Source: Biotech’s boom spells a spike in R&D down payments

    

0 No comments